#4
BioNTech (US Operations)
The mRNA cancer vaccine pioneer with $4B revenue and Phase 3 trials underway for personalized cancer immunotherapy, which outperforms Moderna's oncology pipeline in clinical progress. BioNTech's Oxford partnership and pipeline of mRNA cancer vaccines represent a potential paradigm shift in oncology, with 5 candidate vaccines in development targeting 15% of solid tumors.
Photos (1)
Comments on "BioNTech (US Operations)"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.